Study With Various Immunotherapy Treatments in Participants With Lung Cancer
A phase 2 trial of Domvanalimab, Quemliclustat, Zimberelimab in non-small-cell lung cancer and small-cell lung cancer, run by Gilead Sciences, active and no longer recruiting.
Overview
Study With Various Immunotherapy Treatments in Participants With Lung Cancer is a phase 2 interventional study registered as NCT05676931 by Gilead Sciences, with 400 participants planned, started 2023-02-21 and due to reach its primary completion in 2027-12. Interventions recorded: Domvanalimab, Quemliclustat, Zimberelimab, Docetaxel, Platinum-Based Doublet. Conditions listed: Advanced Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
Shares Quemliclustat, Domvanalimab, Zimberelimab, Gilead Sciences (incl. Kite).
- TrialStudy of Novel Treatment Combinations in Patients With Lung Cancer
Shares Domvanalimab, Zimberelimab, Gilead Sciences (incl. Kite), Small-cell lung cancer.
- TrialStudy of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst
Shares Domvanalimab, Zimberelimab, Gilead Sciences (incl. Kite).
- TrialZimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
Shares Domvanalimab, Gilead Sciences (incl. Kite), Non-small-cell lung cancer.
- TrialStudy of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Shares Gilead Sciences (incl. Kite), Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Shares Domvanalimab, Zimberelimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Shares Domvanalimab, Non-small-cell lung cancer.
- TrialPhase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.